VYNE Therapeutics’ (VYNE) “Buy” Rating Reaffirmed at HC Wainwright

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $5.75 target price on the stock. HC Wainwright’s target price indicates a potential upside of 148.92% from the stock’s current price.

Separately, BTIG Research initiated coverage on shares of VYNE Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $8.00 price target on the stock.

VYNE Therapeutics Price Performance

VYNE stock traded down $0.08 during midday trading on Thursday, hitting $2.31. The company’s stock had a trading volume of 5,221 shares, compared to its average volume of 98,754. The stock has a market capitalization of $34.07 million, a P/E ratio of -2.69 and a beta of 1.13. The company’s fifty day moving average price is $2.80 and its 200 day moving average price is $2.50. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $4.30.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.03). VYNE Therapeutics had a negative net margin of 6,896.55% and a negative return on equity of 43.73%. Equities analysts expect that VYNE Therapeutics will post -0.97 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Patrick G. Lepore acquired 15,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were purchased at an average price of $2.92 per share, for a total transaction of $43,800.00. Following the purchase, the director now directly owns 51,472 shares in the company, valued at approximately $150,298.24. The trade was a 41.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in VYNE Therapeutics during the fourth quarter valued at approximately $68,000. XTX Topco Ltd bought a new position in shares of VYNE Therapeutics in the 4th quarter valued at $70,000. Bridgeway Capital Management LLC bought a new stake in shares of VYNE Therapeutics during the 4th quarter worth $124,000. Adage Capital Partners GP L.L.C. acquired a new stake in VYNE Therapeutics in the fourth quarter valued at about $516,000. Finally, Schonfeld Strategic Advisors LLC boosted its stake in VYNE Therapeutics by 4.8% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after buying an additional 8,058 shares in the last quarter. Institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.